AAPG
Ascentage Pharma Group Internat
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
16.80
▼ 0.52 (3.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
17.15
Prev close
17.32
Day high
17.44
Day low
17.00
Volume
1.73K
Market cap
$1.59B
P/E (TTM)
—
52W range
16.36 – 45.90
Day trading desk
Gap from prior close
-0.98%
Prior close 17.32
VWAP
17.44
-3.69% from price
Relative volume
0.12×
Quiet session
Session range
3.83%
16.80 – 17.44
Position in range
0%
Near session low
ATR (14D)
0.63
3.74% of price
Prior day high
17.99
PDH
Prior day low
16.80
PDL
Bid / ask spread
—
Quote not published
Session volume
1.34K
Avg 11.21K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.53%
-9.2%
1M
-12.03%
-15.8%
3M
-17.72%
-20.8%
6M
-31.81%
-42.9%
YTD
-35.21%
-47.5%
1Y
-63.98%
-84.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AAPG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$1.59B
Enterprise value$1.79B
Revenue (TTM)$642.64M
Gross profit$603.62M
EBITDA$-1.34B
Net income$-1.47B
EPS (TTM)$-2.35
Free cash flow$-974.30M
Total cash$1.90B
Total debt$2.09B
Book value / share$0.89
Shares outstanding93.34M
Float71.48M
Short % of float0.02%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-12.62
PEG ratio—
Price / sales—
Price / book19.17
EV / revenue2.79
EV / EBITDA-1.34
Gross margin93.93%
Operating margin-248.91%
Profit margin-228.54%
Return on equity-236.63%
Return on assets-28.04%
Debt / equity370.18
Current ratio1.22
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $574.12M | $980.65M | $221.98M | $209.71M | — | -41.5% |
| Operating revenue | $499.27M | $939.25M | $193.53M | $209.71M | — | -46.8% |
| Cost of revenue | $48.94M | $29.09M | $30.54M | $22.00M | — | +68.3% |
| Gross profit | $525.18M | $951.57M | $191.44M | $187.71M | — | -44.8% |
| Research & development | $1.14B | $947.25M | $706.97M | $743.10M | — | +20.1% |
| Selling, general & admin | $599.92M | $383.12M | $376.46M | $328.02M | — | +56.6% |
| Total operating expense | $1.72B | $1.32B | $1.06B | $1.04B | — | +30.4% |
| Operating income | -$1.20B | -$369.73M | -$872.64M | -$849.81M | — | -223.9% |
| Net interest income | $28.05M | -$26.61M | -$63.65M | -$43.06M | — | +205.4% |
| Pre-tax income | -$1.24B | -$395.25M | -$932.86M | -$887.17M | — | -212.7% |
| Tax provision | $6.94M | $10.43M | -$7.15M | -$4.25M | — | -33.4% |
| Net income | -$1.24B | -$405.43M | -$925.64M | -$882.92M | — | -206.5% |
| Net income to common | -$1.24B | -$405.43M | -$925.64M | -$882.92M | — | -206.5% |
| Basic EPS | — | -5.36 | -13.12 | -13.40 | -12.28 | — |
| Diluted EPS | — | -5.36 | -13.12 | -13.40 | -12.28 | — |
| EBIT | -$1.18B | -$330.80M | -$836.80M | -$834.39M | — | -257.3% |
| EBITDA | -$1.10B | -$237.63M | -$743.61M | -$771.47M | — | -361.0% |
| Basic shares | — | 75.52M | 70.57M | 65.92M | 63.65M | — |
| Diluted shares | — | 75.52M | 70.57M | 65.92M | 63.65M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $2.46B | $1.24B | $1.07B | $1.48B | +99.3% |
| Cash & short-term investments | $2.46B | $1.24B | $1.07B | $1.48B | +99.3% |
| Accounts receivable | $252.94M | $83.14M | $145.89M | $54.36M | +204.2% |
| Inventory | $28.62M | $6.60M | $16.17M | $9.45M | +333.8% |
| Total current assets | $2.94B | $1.47B | $1.34B | $1.64B | +99.7% |
| Property, plant & equipment | $829.25M | $905.86M | $957.23M | $650.02M | -8.5% |
| Goodwill & intangibles | $90.63M | $100.69M | $110.14M | $109.00M | -10.0% |
| Total assets | $3.96B | $2.62B | $2.50B | $2.83B | +51.4% |
| Total current liabilities | $1.64B | $1.17B | $934.17M | $881.15M | +40.9% |
| Current debt | $1.22B | $769.62M | $606.65M | $510.31M | +57.9% |
| Long-term debt | $742.33M | $868.64M | $1.17B | $1.27B | -14.5% |
| Total debt | $1.98B | $1.67B | $1.80B | $1.79B | +18.7% |
| Total liabilities | $2.63B | $2.34B | $2.43B | $2.42B | +12.2% |
| Retained earnings | -$7.01B | -$5.77B | -$5.37B | -$4.44B | -21.5% |
| Shareholder equity | $1.32B | $264.19M | $60.42M | $408.66M | +401.3% |
| Working capital | $1.30B | $307.55M | $410.00M | $755.34M | +323.0% |
| Net tangible assets | $1.23B | $163.50M | -$49.72M | $299.66M | +654.6% |
| Shares issued | 373.32M | 315.22M | 290.20M | 265.19M | +18.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$1.24B | -$395.25M | -$932.86M | -$887.17M | -212.7% |
| Depreciation & amortisation | $86.48M | $93.17M | $93.19M | $62.91M | -7.2% |
| Stock-based compensation | $20.87M | $20.92M | $31.50M | $22.11M | -0.2% |
| Change in working capital | -$143.50M | $110.97M | -$9.15M | $104.41M | -229.3% |
| Operating cash flow | -$1.17B | -$111.36M | -$726.08M | -$653.91M | -954.4% |
| Capital expenditure | -$27.57M | -$24.29M | -$56.84M | -$236.96M | -13.5% |
| Investing cash flow | -$1.00B | -$362.04M | $21.92M | -$384.61M | -176.2% |
| Share buybacks | -$9.04M | $0 | -$5.92M | -$26.78M | — |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $2.54B | $314.77M | $368.75M | $619.27M | +707.0% |
| Free cash flow | -$1.20B | -$135.65M | -$782.92M | -$890.88M | -785.9% |
| End cash position | $1.20B | $893.10M | $1.04B | $1.35B | +33.9% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $2.46B | $1.66B | $1.24B | +48.3% |
| Cash & short-term investments | $2.46B | $1.66B | $1.24B | +48.3% |
| Accounts receivable | $252.94M | $78.36M | $83.14M | +222.8% |
| Inventory | $28.62M | $8.59M | $6.60M | +233.1% |
| Total current assets | $2.94B | $1.91B | $1.47B | +54.2% |
| Property, plant & equipment | $829.25M | $871.96M | $905.86M | -4.9% |
| Goodwill & intangibles | $90.63M | $95.69M | $100.69M | -5.3% |
| Total assets | $3.96B | $3.05B | $2.62B | +30.1% |
| Total current liabilities | $1.64B | $1.24B | $1.17B | +32.6% |
| Current debt | $1.22B | $833.78M | $769.62M | +45.7% |
| Long-term debt | $742.33M | $882.38M | $868.64M | -15.9% |
| Total debt | $1.98B | $1.72B | $1.67B | +15.4% |
| Total liabilities | $2.63B | $2.37B | $2.34B | +10.9% |
| Retained earnings | -$7.01B | -$6.36B | -$5.77B | -10.2% |
| Shareholder equity | $1.32B | $666.00M | $264.19M | +98.9% |
| Working capital | $1.30B | $669.42M | $307.55M | +94.3% |
| Net tangible assets | $1.23B | $570.31M | $163.50M | +116.3% |
| Shares issued | 373.32M | 349.00M | 315.22M | +7.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.50 | — | — |
| Mar 2026 | -0.58 | — | — |
| Dec 2025 | -0.40 | — | — |
| Sep 2025 | -0.42 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.62 | 1 | $192.02M | — |
| Next quarter | -0.51 | 1 | $234.23M | — |
| Current year | -1.44 | 4 | $667.39M | +16.3% |
| Next year | -1.35 | 4 | $1.51B | +126.7% |
Analyst targets & ownership
Mean target$47.44
High target$55.00
Low target$40.00
Implied upside182.41%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy2 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.04%
Institutions holding11
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.36
-8.48% from price
SMA 20
18.05
-5.81% from price
SMA 50
18.19
-6.52% from price
SMA 100
20.25
-17.04% from price
SMA 200
23.63
-28.07% from price
EMA 12
18.01
-6.74% from price
EMA 26
18.21
-7.77% from price
EMA 50
18.63
-9.83% from price
RSI (14)
37.9
Neutral
MACD (12,26,9)
-0.20
Hist -0.10
ATR (14)
0.63
3.69% of price
Realised vol 30D
54.0%
Annualised
Bollinger upper
19.70
20, 2σ
Bollinger lower
16.39
20, 2σ
50 / 200 cross
Death
18.19 vs 23.63
Trend bias
Below 200
-28.07%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.18
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
54.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-65.2%
Peak to trough
Max drawdown 5Y
-65.2%
Peak to trough
ATR 14
0.63
3.69% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
15.74K
Prior 158.02K
Change vs prior
-90.0%
Shorts covering
% of float
0.02%
Normal
% of shares out
0.02%
Against total outstanding
Days to cover
2.5
Liquid
Float
71.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 15, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 10, 26 | B. Riley Securities | INITIATED | — | Buy |
| Apr 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 26, 26 | BTIG | MAINTAINED | Buy | Buy |
| Dec 4, 25 | Oppenheimer | INITIATED | — | Outperform |
| Nov 24, 25 | Truist Securities | INITIATED | — | Buy |
| Nov 10, 25 | BTIG | INITIATED | — | Buy |
| Nov 5, 25 | Piper Sandler | INITIATED | — | Overweight |
| Mar 27, 25 | JP Morgan | INITIATED | — | Overweight |
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-08-05
Corporate Changes & Voting Matters
6-K · 2026-08-03
Corporate Changes & Voting Matters
6-K · 2026-07-27
Corporate Changes & Voting Matters
6-K · 2026-07-20
Corporate Changes & Voting Matters
6-K · 2026-07-13
Corporate Changes & Voting Matters
6-K · 2026-06-30
Headlines
Ascentage Pharma Group International H1 Earnings Call Highlights
MarketBeat · 3d ago
Ascentage Pharma H1 Loss Widens, Revenue Rises
MT Newswires · 4d ago
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
GlobeNewswire · 4d ago
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
GlobeNewswire · 10d ago
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
GlobeNewswire · 18d ago
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
GlobeNewswire · 18d ago
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
GlobeNewswire · 21d ago
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
Zacks · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.